Liquidia (NASDAQ:LQDA) and Nemus Bioscience (OTCMKTS:NMUS) Head-To-Head Review

Nemus Bioscience (OTCMKTS:NMUS) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

64.5% of Liquidia shares are owned by institutional investors. 2.7% of Nemus Bioscience shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Nemus Bioscience and Liquidia”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemus Bioscience	N/A	N/A	-$19.19 million	($0.09)	-5.57
Liquidia	$158.32 million	42.09	-$68.92 million	$1.37	54.34

Nemus Bioscience has higher earnings, but lower revenue than Liquidia. Nemus Bioscience is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nemus Bioscience has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.

Profitability

This table compares Nemus Bioscience and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemus Bioscience	N/A	N/A	-924.42%
Liquidia	30.74%	149.65%	36.30%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nemus Bioscience and Liquidia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemus Bioscience	0	0	0	0	0.00
Liquidia	2	3	5	1	2.45

Liquidia has a consensus price target of $98.08, suggesting a potential upside of 31.76%. Given Liquidia’s stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Nemus Bioscience.

Summary

Liquidia beats Nemus Bioscience on 13 of the 14 factors compared between the two stocks.

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.